viewImmunoPrecise Antibodies Ltd

ImmunoPrecise Antibodies is expanding its therapeutic offerings as a global full-service antibody provider


The biotech company is the world’s only single source contract resource organization to offer the full complement of antibody discovery platforms


Quick facts: ImmunoPrecise Antibodies Ltd

Price: 18.4 CAD

Market: TSX-V
Market Cap: $309.42 m
  • Biotechnology company that provides state-of-the-art therapeutic antibody discovery across the entire pipeline
  • Offers a complete portfolio of antibody discovery, characterization, and production technologies
  • World’s only single-source contract resource organization to offer the full complement of antibody discovery platforms

What ImmunoPrecise does:

Biotech company ImmunoPrecise Antibodies Ltd (CVE:IPA) (OTCMKTS:IPATF) provides custom antibody development and production services and protein Expression for research and development.

Its aim is to produce these therapeutically relevant antibodies, in a shorter period of time, with the highest probability of progressing to clinical trials.

Since its inception in 1989, ImmunoPrecise has been serving clinical research and biological markets worldwide. Its customers are pharma and biotech companies as well as non-profit research: universities, medical charities and grant-funded collaborations.

The company operates from a state-of-the-art laboratory at the Vancouver Island Technology Park in Victoria, British Columbia, which house its tissue culture and B-cell screening facilities, as well as an animal care unit.

It has subsidiary operations at U-Protein Express B.V., in the Life Science Incubator, Utrecht, and ModiQuest Research, Oss, both in the Netherlands.

ImmunoPrecise wants to emulate the success of Invitrogen, which became Life Technologies before being taken over by Thermo Fisher for US$13.6 billion. Invitrogen’s bedrock business was selling kits for molecular cloning, but a series of well-judged acquisitions transformed it into the go-to supplier to the biotechnology industry.

ImmunoPrecise, which has been around for 25 years but only listed on the Toronto Venture Exchange in 2016, is at the start of a similar journey.

Its services are in high demand, given the changes in the multi-billion-dollar drugs business over the last decade. There has been a shift from the screening of traditional small-molecule chemical pharmaceuticals to bespoke biologicals, many of which are monoclonal antibodies (MABs) designed to safely and effectively tackle cancer, rheumatoid arthritis and even psoriasis.

In the US, insurers have shown a willingness to pay for the treatments, which tend to be quite expensive, while patients are demanding best-in-class biologicals that are highly targeted for grievous diseases and generally less toxic.

How is it doing:

ImmunoPrecise saw revenue more than double year over year for the 12 months ended April 30 to $10.9 million from $5.4 million thanks to its earlier acquisition of ModiQuest Research, now known as IPA Europe. 

The company has also designed a platform to discover the wild-type and fully human components of bispecific antibodies, which means it can generate pairs of bound proteins with antibody backbones and the attributes necessary to bind to molecules. 

The Abthena platform meshes with Artemis Intelligence Metadata, which offers rapid turnaround on additional algorithmic outputs regarding therapeutic optimization, stability, affinity and manufacturability of the antibodies.

In September, Talem Therapeutics announced a new collaboration with clinical-stage biopharmaceutical company AgonOx to develop therapies that use the body's immune system to fight cancer.

It also inked a deal with Ligand Pharmaceuticals (NASDAQ:LGND) for its novel OmniAb platform that allows Talem to access OmniAb to use with its own antibody discovery capabilities.

Inflection points:

  • Expansion of animal facilities to propel preclinical capabilities
  • Potential NASDAQ listing
  • Opening of US research and manufacturing facilities, and US expansion for business development
  • Open to partnerships and collaborations with pharma (outside of fee-for-service)

What the boss says:

In a statement accompanying ImmunoPrecise's most recent financial results, CEO Jennifer Bath commented: “We continue to expand our therapeutic offerings as a global, full-service antibody provider to pharmaceutical and biotech companies internationally, and to accelerate our volume of large-scale, therapeutic programs.

“Simultaneously, IPA sets itself on a path of Antibody Discovery and IP estate-building through Talem Therapeutics, which will expand our clinical partnerships and continue to build our IP estate.” 

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site,...


ImmunoPrecise Antibodies reveals 39% growth in 1Q revenue, initiates...

ImmunoPrecise Antibodies Ltd. (TSX-V:IPA) (OTCQB:IPATF) CEO Dr Jennifer Bath tells Proactive the technology platform company reported revenue increases by 39%, to $3.8 million in its first quarter financials, while the company initiates its pre-clinical coronavirus vaccine study. Bath says new...

on 30/9/20

3 min read